Multitarget stool DNA screening completion

Multitarget stool DNA screening completion is associated with colorectal cancer-free survival in humans (HR 0.76, 95% CI 0.74–0.78).

“mt-sDNA kit return associated with improved CRC-free survival (HR 0.76; 95% CI 0.74-0.78; p < 0.0001).”

HumansAverage-risk adults; kit return compared with non-returnBoths

Return of Mailed Multitarget Stool DNA Test Kits and Subsequent Colorectal Cancer Incidence in the United States: A Retrospective Cohort Study

Advances in therapy·11 Oct 2026

Multitarget stool DNA screening completion is associated with colorectal cancer incidence in humans (55% lower incidence; IRR 0.45, 95% CI 0.45–0.46).

“In adjusted analyses, mt-sDNA kit return was associated with 55% lower CRC incidence versus non-return”

HumansAverage-risk adults; kit return compared with non-return, adjusted analysisBoths

Return of Mailed Multitarget Stool DNA Test Kits and Subsequent Colorectal Cancer Incidence in the United States: A Retrospective Cohort Study

Advances in therapy·11 Oct 2026